Join the RSV Vaccine, Pref A-Pref B, Recombinant group to help and get support from people like you.
RSV Vaccine, Pref A-Pref B, Recombinant News (Page 2)
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 – Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social...
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
RSV Vaccination Effective Against Hospitalization in Patients 60 Years and Older
THURSDAY, Sept. 5, 2024 – For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the Journal of...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
U.S. FDA Approves Abrysvo, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
NEW YORK--(BUSINESS WIRE) August 21, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...
FDA Approves Abrysvo (respiratory syncytial virus vaccine) for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
NEW YORK--(BUSINESS WIRE) May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...
FDA Approves Arexvy (respiratory syncytial virus vaccine, adjuvanted) Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 3, 2023 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower...